ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis.

TitleACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis.
Publication TypeJournal Article
Year of Publication2024
AuthorsGuillet S, Lazarov T, Jordan N, Boisson B, Tello M, Craddock B, Zhou T, Nishi C, Bareja R, Yang H, Rieux-Laucat F, Lorenzo RIrene Freg, Dyall SD, Isenberg D, D'Cruz D, Lachmann N, Elemento O, Viale A, Socci ND, Abel L, Nagata S, Huse M, W Miller T, Casanova J-L, Geissmann F
JournalmedRxiv
Date Published2024 Jun 05
Abstract

Systemic Lupus Erythematosus (SLE) is an autoimmune disease, the pathophysiology and genetic basis of which are incompletely understood. Using a forward genetic screen in multiplex families with systemic lupus erythematosus (SLE) we identified an association between SLE and compound heterozygous deleterious variants in the non-receptor tyrosine kinases (NRTKs) ACK1 and BRK. Experimental blockade of ACK1 or BRK increased circulating autoantibodies in mice and exacerbated glomerular IgG deposits in an SLE mouse model. Mechanistically, non-receptor tyrosine kinases (NRTKs) regulate activation, migration, and proliferation of immune cells. We found that the patients' ACK1 and BRK variants impair efferocytosis, the MERTK-mediated anti-inflammatory response to apoptotic cells, in human induced Pluripotent Stem Cell (hiPSC)-derived macrophages, which may contribute to SLE pathogenesis. Overall, our data suggest that ACK1 and BRK deficiencies are associated with human SLE and impair efferocytosis in macrophages.

DOI10.1101/2024.02.15.24302255
Alternate JournalmedRxiv
PubMed ID38883731
PubMed Central IDPMC11177913
Grant ListR01 AI124349 / AI / NIAID NIH HHS / United States
R01 AI130345 / AI / NIAID NIH HHS / United States
R01 CA058530 / CA / NCI NIH HHS / United States
R01 AI087644 / AI / NIAID NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States